Abstracts Archive - Page 1803 of 2607 - ACR Meeting Abstracts

Abstract Number: 3064 • 2016 ACR/ARHP Annual Meeting
From Art to Science: A Mobile App for Point-of-Care Relevance Determination for the Musculoskeletal Exam
Joy-Ann Tabanor, Joongheum Park, Heidi-Anne Hanson and Hnin Hnin Oo, Department of Medicine, Englewood Hospital and Medical Center, Englewood, NJ
Background/Purpose: The physical exam is an essential part of the assessment of patients with musculoskeletal (MSK) complaints. Few doctors are aware of the sensitivity and specificity…
Abstract Number: 3065 • 2016 ACR/ARHP Annual Meeting
Mortality in Patients with Rheumatoid Arthritis and Interstitial Lung Disease Treated with First Line TNFi or Rituximab Therapies
Katie Druce¹, Kundan Iqbal², Kath Watson¹, Deborah P.M. Symmons¹, Kimme L. Hyrich¹ and Clive Kelly³, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Newcastle University, Newcastle, United Kingdom, ³Rheumatology, Queen Elizabeth Hospital, Gateshead, United Kingdom
Mortality in Patients With Rheumatoid Arthritis and Interstitial Lung Disease Treated With First Line TNFi or Rituximab Therapies Druce KL, Iqbal K, Watson K, Symmons…
Abstract Number: 3066 • 2016 ACR/ARHP Annual Meeting
Risk of Incident Cancer with Biologic and Tofacitinib Therapy in Rheumatoid Arthritis
Bryant R. England¹, Sofia Pedro², Ted R Mikuls³ and Kaleb Michaud^2,4, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The immune system recognizes, controls, and eliminates tumors through a process of immunosurveillance. In RA, where there is an increased incidence of lymphoma and…
Abstract Number: 3067 • 2016 ACR/ARHP Annual Meeting
Treatment Decisions Following Diagnosis of Cancer during TNFi Inhibitor Treatment in Patients with Rheumatoid Arthritis: Results from the BSRBR-RA
Katie Druce¹, Diederik Decock², Kath Watson¹, Deborah P.M. Symmons¹ and Kimme L. Hyrich¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Treatment Decisions Following Diagnosis of Cancer During TNFi inhibitor Treatment in Patients with Rheumatoid Arthritis: results from the BSRBR-RA Druce KL, De Cock D, Watson…
Abstract Number: 3068 • 2016 ACR/ARHP Annual Meeting
Smoking and Excess Weight Attenuate Rate of Improvement over First 3 Years in Early RA
Susan J. Bartlett^1,2, Orit Schieir³, Kathleen Andersen⁴, Gilles Boire⁵, Boulos Haraoui⁶, Carol Hitchon⁷, Edward Keystone⁸, Janet E. Pope⁹, J Carter Thorne¹⁰, Diane Tin¹¹, Vivian P. Bykerk¹² and Canadian Early Arthritis Cohort (CATCH) Investigators, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁶1551, Ontario Street East, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁹University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Early, aggressive treatment to achieve remission is the primary goal when treating early RA, and is associated with improved long-term outcomes. We have previously…
Abstract Number: 3069 • 2016 ACR/ARHP Annual Meeting
Weight Loss in the Early Rheumatoid Arthritis Period Is Associated with Subsequent Increased Mortality in RA Patients and Matched Comparators: Evidence Against an RA-Specific Obesity Paradox
Jeffrey A. Sparks¹, Shun-Chiao Chang², Uyen Sa D.T. Nguyen^3,4, Medha Barbhaiya², Sara K. Tedeschi², Bing Lu², Karen H. Costenbader², Yuqing Zhang⁵, Hyon K. Choi⁶ and Elizabeth W. Karlson², ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA, ⁶Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose : Weight loss may explain the obesity paradox for mortality, since those who unintentionally lose weight to reach normal BMI may have higher mortality…
Abstract Number: 3070 • 2016 ACR/ARHP Annual Meeting
Effect of Sarcopenia, Subcutaneous Adipose Tissue and Abdominal Visceral Fat on Mortality Risk of Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study
Felipe M Santana¹, Michel A Gonçalves², Diogo S Domiciano³, Luana G Machado³, Jaqueline B Lopes³, Camille P Figueiredo³, Valéria Caparbo³, Liliam Takayama³ and Rosa M R Pereira⁴, ¹Deparment of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Department of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil
Background/Purpose: Body composition changes resulting from ageing (decreased muscle mass and increased fat tissue) are frequently not accompanied by concomitant changes in body mass index…
Abstract Number: 3071 • 2016 ACR/ARHP Annual Meeting
Recombinant Human Proteoglycan-4 (rhPRG4) Inhibits Monosodium Urate (MSU) Crystal Phagocytosis By Human Macrophages and Resultant Inflammatory Response
Marwa Qadri¹, Tannin Schmidt², Khaled Elsaid³ and Gregory Jay⁴, ¹Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, ²Kinesiology and Schulich School of Engineering, University of Calgary, Calgary, AB, Canada, ³Biomedical and Pharmaceutical Sciences, Chapman University, Irvine, CA, ⁴Emergency Medicine, Brown University, Providence, RI
Background/Purpose: Gout is an inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in synovial joints. MSU crystals interact with resident macrophages that…
Abstract Number: 3072 • 2016 ACR/ARHP Annual Meeting
Increased Platelet Reactivity in Gout: Relationship to Tophus Burden and Colchicine Use
Richard Conway¹, Claire-Louise Murphy², Anne Madigan³, Patricia Kavanagh⁴, Liz Geraghty³, Niamh Redmond⁵, Laura Helbert⁶, John J. Carey⁷, Eimear Dunne⁸, Dermot Kenny⁸ and Geraldine M. McCarthy⁹, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ³Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁴Rheumatology Department, Mater Public Hospital, Dublin 7, Ireland, ⁵UCD Clinical Research Centre, Dublin, Ireland, ⁶Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁷Rheumatology, Galway University Hospitals, Galway, Ireland, ⁸Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ⁹Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Patients with gout have an increased risk of cardiovascular events. The presence of tophi is associated with enhanced cardiovascular risk. Increased platelet reactivity is…
Abstract Number: 3073 • 2016 ACR/ARHP Annual Meeting
Non-Additive Interaction of the Glucokinase Regulatory Protein and APOBEC1 Complementation Factor Loci with Alcohol Consumption to Influence the Risk of Gout
Humaira Rasheed¹, Lisa K. Stamp², Nicola Dalbeth³ and Tony R. Merriman⁴, ¹University of Engineering and Technology, Lahore, Pakistan, ²University of Otago, Christchurch, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Genome-wide association studies (GWAS) have identified loci associated with serum urate levels and the risk of gout. Some of these loci interact in a…
Abstract Number: 3074 • 2016 ACR/ARHP Annual Meeting
Population-Specific Association Between ABCG2 Variants and Tophaceous Disease in People with Gout
Wendy He¹, Amanda Phipps-Green², Lisa K. Stamp³, Tony R. Merriman⁴ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Dunedin, New Zealand, ³University of Otago, Christchurch, New Zealand, ⁴Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Tophi contribute to musculoskeletal disability, joint damage and poor health-related quality of life in people with gout. The aim of this study was to…
Abstract Number: 3075 • 2016 ACR/ARHP Annual Meeting
Mitochondrial Genetic Variation, Copy Number and Susceptibility to Gout in the New Zealand Polynesian Population
Tony R. Merriman¹, James Boocock², Nicola Dalbeth³, Lisa K. Stamp⁴, Eli A. Stahl⁵, Hyon K. Choi⁶, Elizabeth Matisoo-Smith⁷ and Anna Gosling⁸, ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Boston, MA, ⁶Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, ⁷Anatomy, University of Otago, Dunedin, New Zealand, ⁸Biochemistry, University of Otago, Dunedin, New Zealand
Background/Purpose: Mitochondria play a central role in induction of an NLRP3 inflammatory response essential for gouty pathology. Mitochondria are in part self-encoding, possessing a 16.5…
Abstract Number: 3076 • 2016 ACR/ARHP Annual Meeting
Development of a Matrix-Binding Interlukin-1 Receptor Antagonist Fusion Protein for Extended Retention in the Joint Tissues
James Pancoast¹, Richard Lee^2,3 and Parth Patwari¹, ¹ProteoThera, Inc., Newton, MA, ²Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, ³Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: A primary challenge for intra-articular delivery of protein and peptide therapies has been their short residence time in the joint tissues. The IL-1 receptor…
Abstract Number: 3077 • 2016 ACR/ARHP Annual Meeting
Quiescence in Active and Inactive Non-Infectious, Intermediate, Posterior, or Panuveitis in Patients Treated with Adalimumab
Robert Landewé¹, Irene van der Horst-Bruinsma², Samir Tari³, Stefan Florentinus³, Alexandra P. Song³, Martina Kron⁴, Sophia Pathai⁵ and James T. Rosenbaum^6,7, ¹University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ⁵AbbVie Ltd, Maidenhead, United Kingdom, ⁶Casey Eye Institute, Oregon Health & Science University, Portland, OR, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: There is an unmet need for effective therapies for patients (pts) with non-infectious intermediate, posterior, or panuveitis who are at risk for long-term side…
Abstract Number: 3078 • 2016 ACR/ARHP Annual Meeting
Diffuse Idiopathic Skeletal Hyperostosis and Diabetes- Using Genetic Risk Scores to Explore the Association
Melissa Wang¹, Mariko Ishimori², Greg Kinney³, Irina Ianculsecu¹, Elizabeth Regan⁴, Michael Weisman⁵ and Mark Goodarzi⁶, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Department of Epidemiology, Colorado School of Public Health, Aurora, CO, ⁴Medicine, National Jewish Health, Denver, CO, ⁵Rheumatology, Cedars-Sinai Medical Center, West Hollywood, CA, ⁶Division of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Diffuse Idiopathic Skeletal Hyperostosis (DISH) is a poorly understood condition characterized by new bone formation mainly affecting the spine. An association of DISH with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].